Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure

ClinicalTrials.gov ID: NCT03326843

Public ClinicalTrials.gov record NCT03326843. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Subjects With Thrombocytopenia Scheduled for a Surgical Procedure

Study identification

NCT ID
NCT03326843
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sobi, Inc.
Industry
Enrollment
4 participants

Conditions and interventions

Interventions

  • Avatrombopag 60 mg Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 25, 2018
Primary completion
Feb 24, 2019
Completion
Feb 24, 2019
Last update posted
Apr 14, 2020

2018 – 2019

United States locations

U.S. sites
27
U.S. states
18
U.S. cities
25
Facility City State ZIP Site status
Dova Site Little Rock Arkansas 72205
Dova Site Coronado California 92118
Dova Site Aurora Colorado 80045
Dova Site Jacksonville Florida 32209
Dova Site Jacksonville Florida 32224
Dova Site Miami Florida 33135
Dova Site Miami Florida 33136
Dova Site Pensacola Florida 32503
Dova Site Sarasota Florida 34232
Dova Site Tamarac Florida 33321
Dova Site Tampa Florida 33615
Dova Site New Orleans Louisiana 70112
Dova Site Baltimore Maryland 21202
Dova Site Boston Massachusetts 02115
Dova Site Detroit Michigan 48202
Dova Site Springfield Missouri 65807
Dova Site St Louis Missouri 63110
Dova Site Reno Nevada 89503
Dova Site Englewood New Jersey 07631
Dova Site Buffalo New York 14203
Dova Site Durham North Carolina 27710
Dova Site Winston-Salem North Carolina 27157
Dova Site Toledo Ohio 43606
Dova Site Bethlehem Pennsylvania 18015
Dova Site Austin Texas 78731
Dova Site Newport News Virginia 23602
Dova Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03326843, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 14, 2020 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03326843 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →